WallStSmart
INCY

Incyte Corporation

NASDAQ: INCY · HEALTHCARE · BIOTECHNOLOGY

$99.10
+1.39% today

Updated 2026-04-29

Market cap
$19.80B
P/E ratio
14.00
P/S ratio
3.69x
EPS (TTM)
$7.08
Dividend yield
—
52W range
$58 – $112
Volume
1.6M
OverviewPrice TargetsFinancialsValuationInsidersEarnings

Incyte Corporation (INCY) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current
$99.10
Consensus
$102.00
+2.93%
2030 Target
—
—
DCF
$624.90
+84.18% MoS
21 analysts:
5 Buy9 Hold2 Sell

Management guidance

TD Cowen analyst cited management's roadmap to triple non-Jakafi revenue by 2029, indicating significant pipeline expansion beyond the current flagship drug. CEO Bill Meury emphasizes blood cancer therapy development as the company's central identity, with multiple late-stage programs in dermatology (Povorcitinib for hidradenitis suppurativa) and oncology (Zynyz label expansions) driving growth through 2026-2030.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range
Bull case (2030)
$825.28
—
Base case (2030)
$493.27
—
Bear case (2030)
$332.01
—

Financial forecast — research-backed

Metric2023202420252026 (E)2027 (E)2028 (E)2029 (E)
Revenue$3.7B$4.2B$5.1B$5.7B$6.4B$7.2B$8.3B
Revenue growth—14.8%21.2%11.0%11.3%12.6%15.6%
EPS$3.52$0.79$6.43$7.66$8.98$10.65$12.58
P/S ratio———12.0x12.0x12.0x12.0x
Implied price———$341.50$379.44$426.87$493.27

Catalysts & risks

Growth catalysts
+ Povorcitinib approval and ramp for hidradenitis suppurativa (positive 54-week data announced March 2026)
+ Zynyz (retifanlimab) label expansions in Europe and potential US indications through 2027-2028
+ Non-Jakafi revenue tripling by 2029 per management roadmap (dermatology, oncology, immunology pipeline)
+ Jakafi continued growth in myelofibrosis and polycythemia vera with potential new indications
+ Potential M&A or partnerships to accelerate pipeline commercialization
Key risks
- Competition from JAK inhibitors and PD-1/PD-L1 therapies in core oncology/immunology markets
- Regulatory delays or negative trial outcomes for Povorcitinib or pipeline candidates
- Jakafi revenue plateau if market saturation occurs or generic competition emerges post-patent
- FX headwinds from international revenue exposure (EU approvals)
- Gross margin compression if non-Jakafi products carry lower margins or require higher R&D spend

Methodology

Incyte Corporation's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 21 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.